Upgrade to SI Premium - Free Trial

Regeneron Pharma (REGN) PT Raised to $710 at BMO Capital

November 4, 2021 5:50 PM
BMO Capital analyst Matthew Luchini raised the price target on Regeneron Pharma (NASDAQ: REGN) to $710.00 while maintaining an Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles